{"success":true,"data":{"pressRelease":{"id":"166361","rtpr_id":"nPn9zL5GXa-20261012","ticker":"CTOR","exchange":"NASDAQ","all_tickers":["CTOR","CTXR"],"title":"Citius Pharmaceuticals to Participate in October 2026 Investor Conferences","author":"PR Newswire","published_at":"2026-10-12T12:30:00.091Z","article_body":"Citius Pharmaceuticals to Participate in October 2026 Investor Conferences\nPR Newswire\n\nCRANFORD, N.J., Oct. 12, 2026\n\nChairman and CEO Leonard Mazur to present and host one-on-one investor\nmeetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference\n\nCRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc.\n(\"Citius Pharma\" or the \"Company\") (Nasdaq: CTXR), a biopharmaceutical company\ndedicated to the development and commercialization of first-in-class critical\ncare products, today announced that Chairman and Chief Executive Officer\nLeonard Mazur will present and host one-on-one investor meetings at two\nupcoming investor conferences in New York City.\n\nMr. Mazur will provide an overview of the Company's business and recent\ndevelopments, including the ongoing commercialization of\nLYMPHIR(®) (denileukin diftitox-cxdl) by the Company's majority-owned\nsubsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).\n\nMaxim Growth Summit:\n\n * Conference: 2026 Maxim Growth Summit\n * Dates: October 12–14, 2026\n * Location: Hard Rock Hotel New York, New York, NY\nInvestors interested in scheduling a one-on-one meeting with management should\ncontact their conference representative or the Company's investor relations\nteam.\n\nThinkEquity Conference:\n\n * Conference: ThinkEquity Conference\n * Date: October 15, 2026\n * Location: Mandarin Oriental, New York, NY\n * Presentation Date & Time: Thursday, October 15, 2026, 3:00-3:30pm ET\nPlease note that the presentation date and time is subject to change.\nParticipants should refer to the final program agenda for up-to-date\ninformation.\n\nInvestors interested in scheduling a one-on-one meeting with management should\ncontact their conference representative or the Company's investor relations\nteam.\n\nAbout Citius Pharmaceuticals, Inc.\nCitius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company\ndedicated to the development and commercialization of first-in-class critical\ncare products. Citius Pharma owns approximately 71% of Citius Oncology. In\nDecember 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for\nthe treatment of adults with relapsed or refractory Stage I–III CTCL who had\nhad at least one prior systemic therapy. Citius Pharma's late-stage pipeline\nalso includes Mino-Lok(®), a catheter lock solution to salvage catheters in\npatients with catheter-related bloodstream infections, and CITI-002\n(Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal\nPhase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed\nin 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial.\nCitius Pharma is actively engaged with the FDA to outline next steps for both\nprograms. For more information, please visit www.citiuspharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795248-1&h=2666328290&u=http%3A%2F%2Fwww.citiuspharma.com%2F&a=www.citiuspharma.com)\n.\n\nAbout Citius Oncology, Inc.\nCitius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and\ncommercialize novel targeted oncology therapies. In December 2025, Citius\nOncology launched LYMPHIR, approved by the FDA for the treatment of adults\nwith relapsed or refractory Stage I–III CTCL who had had at least one prior\nsystemic therapy. Management estimates the initial market for LYMPHIR\ncurrently exceeds $400 million, is growing, and is underserved by existing\ntherapies. Robust intellectual property protections that span orphan drug\ndesignation, complex technology, trade secrets and pending patents for\nimmuno-oncology use as a combination therapy with checkpoint inhibitors would\nfurther support Citius Oncology's competitive positioning. For more\ninformation, please visit www.citiusonc.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795248-1&h=2893708717&u=http%3A%2F%2Fwww.citiusonc.com%2F&a=www.citiusonc.com)\n.\n\nInvestor Contact:\nIlanit Allen\nir@citiuspharma.com (mailto:ir@citiuspharma.com)\n908-967-6677 x113\n\nMedia Contact:\nSTiR-communications\nGreg Salsburg\nGreg@STiR-communications.com (mailto:Greg@STiR-communications.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-october-2026-investor-conferences-302905224.html\n(https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-october-2026-investor-conferences-302905224.html)\n\nSOURCE Citius Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS967916/Citius-32.jpg?id=OA3012058\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9zL5GXa-20261012","title":"Citius Pharmaceuticals to Participate in October 2026 Investor Conferences","author":"PR Newswire","ticker":"CTOR","created":"2026-10-12T12:30:00.091Z","tickers":["CTOR","CTXR"],"exchange":"NASDAQ","article_body":"Citius Pharmaceuticals to Participate in October 2026 Investor Conferences\nPR Newswire\n\nCRANFORD, N.J., Oct. 12, 2026\n\nChairman and CEO Leonard Mazur to present and host one-on-one investor\nmeetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference\n\nCRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc.\n(\"Citius Pharma\" or the \"Company\") (Nasdaq: CTXR), a biopharmaceutical company\ndedicated to the development and commercialization of first-in-class critical\ncare products, today announced that Chairman and Chief Executive Officer\nLeonard Mazur will present and host one-on-one investor meetings at two\nupcoming investor conferences in New York City.\n\nMr. Mazur will provide an overview of the Company's business and recent\ndevelopments, including the ongoing commercialization of\nLYMPHIR(®) (denileukin diftitox-cxdl) by the Company's majority-owned\nsubsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).\n\nMaxim Growth Summit:\n\n * Conference: 2026 Maxim Growth Summit\n * Dates: October 12–14, 2026\n * Location: Hard Rock Hotel New York, New York, NY\nInvestors interested in scheduling a one-on-one meeting with management should\ncontact their conference representative or the Company's investor relations\nteam.\n\nThinkEquity Conference:\n\n * Conference: ThinkEquity Conference\n * Date: October 15, 2026\n * Location: Mandarin Oriental, New York, NY\n * Presentation Date & Time: Thursday, October 15, 2026, 3:00-3:30pm ET\nPlease note that the presentation date and time is subject to change.\nParticipants should refer to the final program agenda for up-to-date\ninformation.\n\nInvestors interested in scheduling a one-on-one meeting with management should\ncontact their conference representative or the Company's investor relations\nteam.\n\nAbout Citius Pharmaceuticals, Inc.\nCitius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company\ndedicated to the development and commercialization of first-in-class critical\ncare products. Citius Pharma owns approximately 71% of Citius Oncology. In\nDecember 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for\nthe treatment of adults with relapsed or refractory Stage I–III CTCL who had\nhad at least one prior systemic therapy. Citius Pharma's late-stage pipeline\nalso includes Mino-Lok(®), a catheter lock solution to salvage catheters in\npatients with catheter-related bloodstream infections, and CITI-002\n(Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal\nPhase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed\nin 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial.\nCitius Pharma is actively engaged with the FDA to outline next steps for both\nprograms. For more information, please visit www.citiuspharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795248-1&h=2666328290&u=http%3A%2F%2Fwww.citiuspharma.com%2F&a=www.citiuspharma.com)\n.\n\nAbout Citius Oncology, Inc.\nCitius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and\ncommercialize novel targeted oncology therapies. In December 2025, Citius\nOncology launched LYMPHIR, approved by the FDA for the treatment of adults\nwith relapsed or refractory Stage I–III CTCL who had had at least one prior\nsystemic therapy. Management estimates the initial market for LYMPHIR\ncurrently exceeds $400 million, is growing, and is underserved by existing\ntherapies. Robust intellectual property protections that span orphan drug\ndesignation, complex technology, trade secrets and pending patents for\nimmuno-oncology use as a combination therapy with checkpoint inhibitors would\nfurther support Citius Oncology's competitive positioning. For more\ninformation, please visit www.citiusonc.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4795248-1&h=2893708717&u=http%3A%2F%2Fwww.citiusonc.com%2F&a=www.citiusonc.com)\n.\n\nInvestor Contact:\nIlanit Allen\nir@citiuspharma.com (mailto:ir@citiuspharma.com)\n908-967-6677 x113\n\nMedia Contact:\nSTiR-communications\nGreg Salsburg\nGreg@STiR-communications.com (mailto:Greg@STiR-communications.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-october-2026-investor-conferences-302905224.html\n(https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-october-2026-investor-conferences-302905224.html)\n\nSOURCE Citius Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS967916/Citius-32.jpg?id=OA3012058\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-12T12:30:00.143611643Z","server_sent_at_ms":1791808200143},"received_at":"2026-10-12T12:30:00.193Z","source_url":"https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-october-2026-investor-conferences-302905224.html"},"analysis":{"id":"154729","press_release_id":"166361","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Citius Pharmaceuticals announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the 2026 Maxim Growth Summit (October 12-14) and the ThinkEquity Conference (October 15) in New York City.\n\nPresentations will cover recent developments including the ongoing commercialization of LYMPHIR, the CTCL immunotherapy launched in December 2025 by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR).\n\nThe release is a routine conference-participation notice with no new financial or regulatory disclosures.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor-conference schedule announcement -- no new catalyst information."},"keyFigures":{"customDimensions":{"lympir_market_estimate":"$400 million","citius_pharma_ownership_of_oncology":"approximately 71%"}},"namedEntities":{"people":[{"name":"Leonard Mazur","role":"Chairman and CEO"},{"name":"Ilanit Allen","role":"Investor Contact"},{"name":"Greg Salsburg","role":"Media Contact, STiR-communications"}],"products":["LYMPHIR (denileukin diftitox-cxdl)","Mino-Lok","CITI-002 (Halo-Lido)"],"companies":[{"name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","relationship":"parent / issuer of the release"},{"name":"Citius Oncology, Inc.","ticker":"CTOR","relationship":"majority-owned subsidiary of Citius Pharmaceuticals"},{"name":"Maxim Growth Summit","relationship":"conference host"},{"name":"ThinkEquity Conference","relationship":"conference host"}],"dollarAmounts":[{"amount":"$400 million","context":"management estimate of initial LYMPHIR market size"}]},"materialImpact":{"score":1,"reasoning":"Routine investor-conference participation announcement with no new financial, regulatory, or pipeline information. Boilerplate company description only."},"tickerRelevance":{"others":[{"ticker":"CTXR","relevance":"parent company / issuer of the release; Citius Pharma owns approximately 71% of CTOR"}],"primary":"CTOR"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap biotech","eventGravity":"conference participation notice","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Citius Pharmaceuticals announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the 2026 Maxim Growth Summit (October 12-14) and the ThinkEquity Conference (October 15) in New York City.\n\nPresentations will cover recent developments including the ongoing commercialization of LYMPHIR, the CTCL immunotherapy launched in December 2025 by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR).\n\nThe release is a routine conference-participation notice with no new financial or regulatory disclosures.","key_figures":{"customDimensions":{"lympir_market_estimate":"$400 million","citius_pharma_ownership_of_oncology":"approximately 71%"}},"named_entities":{"people":[{"name":"Leonard Mazur","role":"Chairman and CEO"},{"name":"Ilanit Allen","role":"Investor Contact"},{"name":"Greg Salsburg","role":"Media Contact, STiR-communications"}],"products":["LYMPHIR (denileukin diftitox-cxdl)","Mino-Lok","CITI-002 (Halo-Lido)"],"companies":[{"name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","relationship":"parent / issuer of the release"},{"name":"Citius Oncology, Inc.","ticker":"CTOR","relationship":"majority-owned subsidiary of Citius Pharmaceuticals"},{"name":"Maxim Growth Summit","relationship":"conference host"},{"name":"ThinkEquity Conference","relationship":"conference host"}],"dollarAmounts":[{"amount":"$400 million","context":"management estimate of initial LYMPHIR market size"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T12:30:06.118Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap biotech","eventGravity":"conference participation notice","issuerAuthored":true,"newInformation":false}},"durationMs":5910,"modelName":"glm-5.3-flashx"}}